Company intelligence / Profile preview

Rampart America

Monrovia, California, United Statesfacebook.com ↗

Ownership: Private
Employees: ~35
Development stage: Other

Overview

Rampart Bioscience is developing a proprietary non‑viral gene therapy platform ("HALO") designed to overcome safety and durability limitations of viral vectors. Its lead program targets hypophosphatasia, a rare genetic bone disorder. The company has raised significant venture funding and aims to deliver potent, durable, redosable therapies for genetically driven diseases. No human clinical results have been published as of June 2025.

Therapeutic areas: Rare Diseases
Modalities: DNA-based gene therapyBiologic (as next-generation biologics)
Industry: Biotech

Partnerships

No major pharmaceutical partnerships disclosed as of June 2025.

Beyond the preview

Go deeper on Rampart America.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rampart America.

Explore the full profile